1 Title

2 C-type natriuretic peptide facilitates autonomic Ca²⁺ entry in growth plate chondrocytes for 3 stimulating bone growth

4 Authors

5 Yuu Miyazaki^{1#}, Atsuhiko Ichimura^{1#}, Ryo Kitayama¹, Naoki Okamoto¹, Tomoki Yasue¹, Feng Liu¹,
6 Yohei Ueda², Ichiro Yamauchi², Takuro Hakata², Kazumasa Nakao², Sho Kakizawa¹, Miyuki Nishi¹,
7 Yasuo Mori³, Haruhiko Akiyama⁴, Kazuwa Nakao⁵ and Hiroshi Takeshima^{1*}

8 Author affiliations

9 ¹Graduate School of Pharmaceutical Sciences, ²Graduate School of Medicine, ³Graduate School of
10 Engineering and ⁵Medical Innovation Center, Kyoto University, Kyoto 606-8501, Japan.

11 ⁴Graduate School of Medicine, Gifu University, Gifu 501-1194, Japan.

12 Author list footnotes

13 [#]These authors contributed equally to this study.

14 *For correspondence: Hiroshi Takeshima (takeshima.hiroshi.8m@kyoto-u.ac.jp) Department of
15 Biological Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto
16 606-8501, Japan.

17 Tel: +81-75-753-4572; Fax: +81-75-753-4605

18

19 **Abstract**

20 The growth plates are cartilage tissues found at both ends of developing bones, and vital proliferation
 21 and differentiation of growth plate chondrocytes are primarily responsible for bone growth. C-type
 22 natriuretic peptide (CNP) stimulates bone growth by activating natriuretic peptide receptor 2 (NPR2)
 23 which is equipped with guanylate cyclase on the cytoplasmic side, but its signaling pathway is
 24 unclear in growth plate chondrocytes. We previously reported that transient receptor potential
 25 melastatin-like 7 (TRPM7) channels mediate intermissive Ca^{2+} influx in growth plate chondrocytes,
 26 leading to activation of Ca^{2+} /calmodulin-dependent protein kinase II (CaMKII) for promoting bone
 27 growth. In this report, we provide experimental evidence indicating a functional link between CNP
 28 and TRPM7 channels. Our pharmacological data suggest that CNP-evoked NPR2 activation elevates
 29 cellular cGMP content and stimulates big-conductance Ca^{2+} -dependent K^+ (BK) channels as a
 30 substrate for cGMP-dependent protein kinase (PKG). BK channel-induced hyperpolarization likely
 31 enhances the driving force of TRPM7-mediated Ca^{2+} entry and seems to accordingly activate
 32 CaMKII. Indeed, *ex vivo* organ culture analysis indicates that CNP-facilitated bone growth is
 33 abolished by chondrocyte-specific *Trpm7* gene ablation. The defined CNP signaling pathway, the
 34 NPR2-PKG-BK channel-TRPM7 channel-CaMKII axis, likely pinpoints promising target proteins

35 for developing new therapeutic treatments for divergent growth disorders.

36

37

38 **Introduction**

39 The development of skeletal long bones occurs through endochondral ossification processes, during
 40 which chondrocyte layers form the growth plates at both ends of bone rudiments, and then the
 41 expanded cartilage portions are gradually replaced by trabecular bones through the action of
 42 osteoclasts and osteoblasts [1]. Therefore, bone size largely depends on the proliferation of growth
 43 plate chondrocytes during endochondral development. On the other hand, atrial (ANP), brain (BNP)
 44 and C-type (CNP) natriuretic peptides regulate diverse cellular functions by activating the receptor
 45 guanylate cyclases, NPR1 and NPR2 [2]. Of the natriuretic peptides, CNP exclusively stimulates
 46 bone development by acting on growth plate chondrocytes expressing the CNP-specific receptor
 47 NPR2 [2-4]. Indeed, loss- and gain-of-function mutations in the human *NPR2* gene cause
 48 acromesomelic dysplasia and skeletal overgrowth disorder, respectively [5, 6]. Furthermore,
 49 translational studies have been probing the benefits of CNP treatments in various animal models with
 50 impaired skeletal growth, and a phase III clinical trial of CNP therapy has recently started in patients
 51 with chondrodystrophia primarily resulting from mutations in the *FGFR3* gene [7]. It is thus likely

that NPR2 guanylate cyclase controls chondrocytic cGMP content during growth plate development. Downstream of NPR2 activation, cGMP-dependent protein kinase (PKG) seems to phosphorylate target proteins to facilitate growth plate chondrogenesis [4]. Activated PKG is postulated to stimulate the biosynthesis of growth plate extracellular matrix by playing an inhibitory role in the mitogen-activated protein kinase Raf-MEK-ERK cascade [8]. In parallel, glycogen synthase kinase 3 β (GSK3 β) is likely activated by PKG-mediated phosphorylation, leading to the hypertrophic maturation of growth plate chondrocytes [9]. However, it is still unclear how CNP promotes bone growth at the molecular level, and it is important to further address CNP signaling cascade in growth plate chondrocytes.

In the transient receptor potential channel superfamily, the melastatin subfamily member 7 (TRPM7) forms a mono- and divalent cation-permeable channel in various cell types and participates in important cellular processes including cell growth and adhesion [10]. We recently reported that growth plate chondrocytes generate autonomic intracellular Ca²⁺ fluctuations, which are generated by the intermittent gating of TRPM7 channels, and also that TRPM7-mediated Ca²⁺ entry activates Ca²⁺/calmodulin-dependent protein kinase II (CaMKII), facilitating chondrogenesis for endochondral bone development [11]. Based on these observations, we explored the link between CNP signaling and TRPM7-mediated Ca²⁺ entry through the experiments described in this report. Our data obtained

clearly indicate that big-conductance Ca^{2+} -dependent K^+ (BK) channels play a key role in the functional coupling between NPR2 and TRPM7 channels in growth plate chondrocytes.

Results

CNP facilitates spontaneous Ca^{2+} fluctuations in growth plate chondrocytes

In the growth plates of developing bones, proliferating cartilage cells, designated as round and columnar chondrocytes, frequently exhibit weak increases and decreases in intracellular Ca^{2+} concentration under resting conditions [11]. On the other hand, previous *in vivo* studies demonstrated that CNP application ($>1 \mu\text{mol/kg}$) stimulates endochondral bone growth [2]. In our Fura-2 imaging of round chondrocytes within femoral bone slices prepared from wild-type mice, CNP pretreatments (30~300 nM for 1 hr) dose-dependently facilitated spontaneous Ca^{2+} fluctuations (Figure 1A). In particular, fluctuation-positive cell ratio and fluctuation amplitude were remarkably elevated in response to the CNP treatments. In contrast, ANP treatments exerted no effects on Ca^{2+} fluctuations in growth plate chondrocytes.

In chondrocyte-specific *Npr2*-knockout mice (*Npr2*^{fl/fl}, *Col2a1-Cre*^{+/-}), Cre recombinase is expressed under the control of the collagen type 2 α 1 gene promoter and thus inactivates the floxed

86 *Npr2* alleles in a chondrocyte-specific manner [12]. Our RT-PCR analysis indicated that the floxed
 87 *Npr2* gene was largely inactivated in the growth plates prepared from the E17.5 mutant embryos, but
 88 such recombination events were not detected in other tissues examined (Figure 1-figure supplement
 89 1A and B). Accordingly, *Npr2* mRNA contents in the mutant growth plates were reduced to less than
 90 40% of controls (Figure 1-figure supplement 1C), despite the growth plate preparations contain not
 91 only chondrocytes but also perichondrium-resident cells including undifferentiated mesenchymal
 92 cells and immature chondroblasts. In contrast to the imaging observations in wild-type and control
 93 bone slices, CNP treatments failed to enhance Ca^{2+} fluctuations in the mutant round chondrocytes
 94 prepared from the chondrocyte-specific *Npr2*-knockout mice (Figure 1B). Therefore, CNP seems to
 95 facilitate spontaneous Ca^{2+} fluctuations downstream of NPR2 activation in growth plate
 96 chondrocytes.

97

98 ***Activated PKG facilitates spontaneous Ca^{2+} fluctuations***

99 CNP binds to NPR2 to activate its intrinsic guanylate cyclase and thus stimulates PKG by
 100 elevating cellular cGMP contents [2]. CNP also binds to NPR3 which acts as a decoy receptor for
 101 ligand clearance, but the *Npr3* gene seemed to be inactive in growth plate chondrocytes (Figure
 102 1-figure supplement 2). Next, we pharmacologically verified the contribution of PKG to

103 CNP-facilitated Ca^{2+} fluctuations. The cGMP analog 8-(4-chlorophenylthio)-cyclic GMP
 104 (8-pCPT-cGMP) is widely used as a PKG-selective activator, while KT5823 is a typical PKG
 105 inhibitor. In wild-type growth plate chondrocytes pretreated with 8-pCPT-cGMP (100 μM for 1 hr),
 106 spontaneous Ca^{2+} fluctuations were remarkably facilitated (Figure 2A); both fluctuation-positive cell
 107 rate and fluctuation amplitude were highly increased. In contrast, the bath application of KT5823 (2
 108 μM) clearly attenuated CNP-facilitated Ca^{2+} fluctuations within a short time frame (Figure 2B).
 109 Therefore, PKG activation seems to be essential for CNP-facilitated Ca^{2+} fluctuations in growth plate
 110 chondrocytes.

111

112 *Activated BK channels contribute to CNP-facilitated Ca^{2+} fluctuations*

113 Spontaneous Ca^{2+} fluctuations are facilitated by activated BK channels in growth plate
 114 chondrocytes [11]. Previous studies have established a functional link between PKG and BK
 115 channels in several cell types including smooth muscle and endothelial cells; activated PKG
 116 enhances BK channel gating by directly phosphorylating the α subunit KCNMA1 protein [13-15].
 117 We thus examined whether altered BK channel activity is associated with CNP-facilitated Ca^{2+}
 118 fluctuations. The BK channel inhibitor paxilline (10 μM) exerted no obvious effects on basal Ca^{2+}
 119 fluctuations in non-treated chondrocytes. However, the same paxilline treatments remarkably

120 inhibited CNP-facilitated Ca^{2+} fluctuations (Figure 3A); both fluctuation-positive cell ratio and
121 fluctuation amplitude were clearly decreased after paxilline application. On the other hand, the BK
122 channel activator NS1619 (30 μM) stimulated basal Ca^{2+} fluctuations in the growth plate
123 chondrocytes prepared from control mice. The NS1619-induced effects were preserved in the mutant
124 chondrocytes prepared from chondrocyte-specific *Npr2*-knockout mice (Figure 3B). Therefore, BK
125 channel activation is likely involved in CNP-facilitated Ca^{2+} fluctuations in growth plate
126 chondrocytes.

127

128 *PLC seems unrelated to CNP-facilitated Ca^{2+} fluctuations*

129 Ca^{2+} fluctuations are maintained by phosphatidylinositol (PI) turnover in growth plate
130 chondrocytes [11]. Although it has been reported that activated PKG inhibits phospholipase C (PLC)
131 in smooth muscle [16-19], it might be possible that NPR2 activation enhances basal PLC activity to
132 facilitate Ca^{2+} fluctuations. The PLC inhibitor U73122 (10 μM) remarkably inhibited basal Ca^{2+}
133 fluctuations in non-treated chondrocytes: the fluctuation-positive cell ratio and fluctuation amplitude
134 reduced less than half in response to U73122 application (Figure 3-figure supplement 3). U73122
135 was also effective for CNP-facilitated Ca^{2+} fluctuations, but the inhibitory efficiency seemed
136 relatively weak compared to those on basal fluctuations. Given the different inhibitory effects, it is

137 rather unlikely that PLC activation accompanies CNP-facilitated Ca^{2+} fluctuations.

138 PKG stimulates sarco/endoplasmic reticulum Ca^{2+} -ATPase (SERCA) by phosphorylating the
 139 Ca^{2+} pump regulatory peptide phospholamban (PLN) in smooth and cardiac muscle cells [20-22],
 140 and activated Ca^{2+} pumps generally elevate stored Ca^{2+} content and thus stimulate store Ca^{2+} release.
 141 RT-PCR data suggested that the *Pln* gene and the *Atp2a2* gene encoding SERCA2 are weakly active
 142 in growth plate chondrocytes (Figure 1-figure supplement 2). To examine the effects of CNP
 143 treatments on Ca^{2+} stores, we examined Ca^{2+} responses to the activation of Gq-coupled
 144 lysophosphatidic acid (LPA) receptors (Figure 3-figure supplement 4A) and the Ca^{2+} pump inhibitor
 145 thapsigargin (Figure 3-figure supplement 4B). CNP- and vehicle-pretreated chondrocytes exhibited
 146 similar LPA-induced Ca^{2+} release and thapsigargin-induced Ca^{2+} leak responses. Therefore, CNP
 147 treatments seem ineffective for store Ca^{2+} pumps in growth plate chondrocytes. Moreover, the
 148 dose-dependency of Ca^{2+} release by LPA (1~10 μM) was not altered between CNP- and
 149 vehicle-pretreated chondrocytes, implying that CNP does not affect basal PLC activity.

150 Among diverse Ca^{2+} handling-related proteins, PLC, PLN and BK channels have been reported
 151 as PKG substrates, however, our observations suggested that both PLC and PLN receive no obvious
 152 functional regulation in CNP-treated chondrocytes. On the other hand, the paxilline treatments
 153 diminished CNP-facilitated Ca^{2+} fluctuations down to non-treated control levels (Figure 3A),

suggesting that activated BK channels predominantly contribute to CNP-facilitated Ca^{2+} fluctuations in growth plate chondrocytes.

CNP induces BK channel-mediated hyperpolarization

To confirm the contribution of activated BK channels to CNP-facilitated Ca^{2+} fluctuations, we conducted confocal imaging using the voltage-dependent dye oxonol VI. In this imaging analysis, depolarization results in the accumulation of the dye into cells, in which the fractional fluorescence intensity, normalized to the maximum intensity monitored in the bath solution containing 100 mM KCl, is thus increased (Figure 4A left panel). The fractional intensity of CNP-pretreated cells was significantly lower than that of non-treated cells in a normal bath solution (Figure 4A middle graph), although both cells exhibited similar intensity shifts in high K^+ bath solutions. Based on the recording data, we prepared a calibration plot for the relationship between the fractional intensity and theoretical membrane potential (Figure 4A right panel). In the tentative linear correlation, resting potentials of -46.4 ± 0.2 and -43.6 ± 0.3 mV were estimated in CNP-treated and non-treated cells, respectively. The estimated potentials closely approximate the reported value from monitoring articular chondrocytes using sharp microelectrodes [23].

In pharmacological assessments, paxilline elevated fractional intensities to the same levels in

CNP-and non-treated chondrocytes (Figure 4B). Moreover, NS1619 decreased fractional intensities to the same levels in both cells under 20 mM KCl bathing conditions, which enabled us to reliably evaluate the reducing intensity shifts (Figure 4C). The oxonol VI imaging data suggested that CNP treatments induce BK channel-mediated hyperpolarization and thus facilitate spontaneous Ca^{2+} fluctuations by enhancing Ca^{2+} -driving forces in growth plate chondrocytes.

CNP enhances TRPM7-mediated Ca^{2+} entry and CaMKII activity

Spontaneous Ca^{2+} fluctuations are predominantly attributed to the intermissive gating of cell-surface TRPM7 channels in growth plate chondrocytes [11]. For pharmacological characterization of TRPM7 channels, FTY720 is used as a typical inhibitor, while NNC550396 is an activator. As reasonably expected, bath application of FTY720 (10 μM) clearly diminished CNP-facilitated Ca^{2+} fluctuations in round chondrocytes (Figure 5A). On the other hand, NNC550396 (30 μM) remarkably facilitated Ca^{2+} fluctuation in non-treated chondrocytes, and this facilitation was preserved in the mutant chondrocytes prepared from chondrocyte-specific *Npr2*-knockout mice (Figure 5B). Therefore, CNP treatments likely facilitate TRPM7-mediated Ca^{2+} influx in growth plate chondrocytes.

TRPM7-mediated Ca^{2+} entry activates CaMKII in growth plate chondrocytes toward bone

outgrowth [11], and cellular CaMKII activity can be estimated by immunochemically quantifying its autophosphorylated form. In immunocytochemical analysis, CNP-pretreated growth plate chondrocytes were more decorated with the antibody against phospho-CaMKII than non-treated control cells (Figure 6A). This CNP-facilitated decoration was abolished by the cotreatment of the CaMKII inhibitor KN93 (30 μ M). This observation was further confirmed by Western blot analysis; CNP treatments increased the phospho-CaMKII population without affecting total CaMKII content in the cell lysates prepared from growth plates (Figure 6B). Therefore, CaMKII is likely activated downstream of enhanced TRPM7-mediated Ca^{2+} entry in CNP-treated growth plate chondrocytes.

Pharmacologically activated BK channels facilitate bone outgrowth

Based on the present data from *in vitro* experiments, the novel CNP-signaling route, represented as the NPR2-PKG-BK channel-TRPM7 channel-CaMKII axis, can be proposed in growth plate chondrocytes. We attempted to examine the proposed signaling axis in metatarsal bone culture, a widely used *ex vivo* model system for analyzing bone growth and endochondral ossification [24]. In chondrocyte-specific *Trpm7*-knockout mice (*Trpm7*^{fl/fl}, *11Enh-Cre*^{+/-}), Cre recombinase is expressed under the control of the collagen type XI gene enhancer and promoter, and thus inactivates the floxed *Trpm7* alleles in cartilage cells [11]. The bone rudiments prepared from control embryos (*Trpm7*^{fl/fl},

205 *11Enh-Cre^{-/-}*) regularly elongated during *ex vivo* culture, and their outgrowth was significantly
206 stimulated by the supplementation with CNP (30 nM) into the culture medium (Figure 7A). In
207 contrast, the mutant rudiments prepared from the chondrocyte-specific *Trpm7*-knockout embryos
208 were reduced in initial size and did not respond to the CNP supplementation. Therefore,
209 CNP-facilitated bone outgrowth seems to require TRPM7 channels expressed in growth plate
210 chondrocytes.

211 In our proposed signaling axis, activated BK channels exert an essential role by converting the
212 chemical signal into the electrical signal. We finally examined the effect of the BK channel activator
213 NS1619 on bone outgrowth (Figure 7B). NS1619 supplementation (30 μ M) significantly stimulated
214 the outgrowth of wild-type bone rudiments. In contrast, under the same culture conditions, no
215 stimulation was detected in the mutant rudiments from the chondrocyte-specific *Trpm7*-deficient
216 embryos. The observations in the bone culture support our conclusion that CNP activates BK
217 channels and thus facilitates TRPM7-mediated Ca^{2+} influx in growth plate chondrocytes, stimulating
218 bone growth.

219

220

221 Discussion

222 We reported that in growth plate chondrocytes, PLC and BK channels maintain autonomic
223 TRPM7-mediated Ca^{2+} fluctuations, which potentiate chondrogenesis and bone growth by activating
224 CaMKII [11]. Based on the present data, together with the previous reports, we proposed a new CNP
225 signaling axis in growth plate chondrocytes (Figure 7-figure supplement 5A). CNP-induced NPR2
226 activation elevates cellular cGMP content and thus activates PKG, leading to the phosphorylation of
227 BK channels. The resulting BK channel activation likely induces cellular hyperpolarization to
228 facilitate TRPM7-mediated Ca^{2+} entry by enhancing the Ca^{2+} driving force, leading to CaMKII
229 activation. Therefore, it is likely that CaMKII activity is physiologically regulated by BK channels as
230 a key player of the CNP signaling cascade. In a recent genetic study, several patients carrying
231 loss-of-function mutations in the *KCNMA1* gene encoding BK channel α subunit were characterized
232 by a novel syndromic growth deficiency associated with severe developmental delay, cardiac
233 malformation, bone dysplasia and dysmorphic features [25]. In the *KCNMA1*-mutated disorder, CNP
234 signaling likely fails to facilitate TRPM7-mediated Ca^{2+} fluctuations in growth plate chondrocytes
235 and resulting insufficient Ca^{2+} entry may lead to systemic bone dysplasia associated with stunted
236 growth plate cartilage. On the other hand, the origin of CNP may still be ambiguous in the signaling
237 scheme. Transgenic mice overexpressing CNP in a chondrocyte-specific manner develop a
238 prominent skeletal overgrowth phenotype, suggesting autocrine CNP signaling [26]. However,

several genechip data in public databases indicate that prepro-CNP mRNA is abundantly expressed in the placenta among embryonic tissues (for example, see the records under accession number GSE28277 in NCBI database). Therefore, it may be important to further examine which cell type primarily produces CNP to facilitate bone growth during embryonic development.

From a physiological point of view, it is interesting to note that the proposed CNP signaling axis has clear overlap with the nitric oxide (NO) and ANP/BNP signaling cascades for vascular relaxation [27-29]. In blood vessels, NO is produced by endothelial cells in response to various stimuli including shear stress and acetylcholine, and activates soluble guanylate cyclase in neighboring vascular smooth muscle cells. ANP and BNP are released from the heart in response to pathological stresses, such as atrial distension and pressure overload, and are delivered to activate the receptor guanylate cyclase NPR1 in vascular muscle. In either case, the resulting cGMP elevation followed by PKG activation induces BK channel-mediated hyperpolarization and thus inhibits L-type Ca^{2+} channel gating, leading to vascular dilation due to decreased Ca^{2+} entry into vascular muscle. Therefore, activated BK channels inhibit the voltage-dependent Ca^{2+} influx in vascular muscle cells regarded as excitable cells (Figure 7-figure supplement 5B). In contrast, activated BK channels reversely stimulate TRPM7-mediated Ca^{2+} entry in growth plate chondrocytes classified as nonexcitable cells, because the channel activity is voltage-independently maintained by the intrinsic

256 PI turnover rate.

257 CNP is an effective therapeutic reagent for achondroplasia and divergent short statures [26, 30,
258 31], and the phase III clinical trial of CNP therapy is now ongoing [2]. The proteins contributing to
259 the CNP signaling axis may be new pharmaceutical targets for developing medications; in addition to
260 NPR2, BK and TRPM7 channels are reasonably considered promising targets. Moreover,
261 phosphodiesterase subtypes might be useful targets, although the subtypes responsible for cGMP
262 hydrolysis remain to be identified in growth plate chondrocytes. Chemical compounds specifically
263 targeting the signaling axis defined in this study would be useful drugs for not only clinical treatment
264 of developmental disorders but also artificially modifying body sizes in farm and pet animals.

265

266 **Materials and Methods**

267 ***Reagents, primers and mice***

268 Reagents and antibodies used in this study are listed in Key Resources Table. Synthetic primers
269 used for RT-PCR analysis and mouse genotyping are also listed in Key Resources Table. C57BL
270 mice were used as wild-type mice in this study. Chondrocyte-specific *Trpm7*-knockout mice with
271 C57BL genetic background were generated and genotyped as previously described [11].
272 Chondrocyte-specific *Npr2*-knockout mice with C57BL background were generated as previously

described [12], and we newly designed primers for detecting the *Col2a1-Cre* transgene and the floxed *Npr2* gene in this study (Figure 1-figure supplement 1). All experiments in this study were conducted with the approval of the Animal Research Committee according to the regulations on animal experimentation at Kyoto University.

Bone slice preparations

Femoral bones were isolated from E17.5 mice and immersed in a physiological salt solution (PSS): (in mM) 150 NaCl, 4 KCl, 1 MgCl₂, 2 CaCl₂, 5.6 glucose, and 5 HEPES (pH 7.4). Longitudinal bone slices (~40 μm thickness) were prepared using a vibrating microslicer (DTK-1000N, Dosaka EM Co., Japan) as previously described [11].

Ca²⁺ imaging

Fura-2 Ca²⁺ imaging of bone slices was performed as previously described [11]. Briefly, bone slices placed on glass-bottom dishes (Matsunami, Japan) were incubated in PSS containing 15 μM Fura-2AM for 1 hr at 37°C. For ratiometric imaging, excitation light of 340 and 380 nm was alternately delivered, and emission light of >510 nm was detected by a cooled EM-CCD camera (Model C9100-13; Hamamatsu Photonics, Japan) mounted on an upright fluorescence microscope

(DM6 FS, Leica, Germany) using a 40x water-immersion objective (HCX APO L, Leica). In typical measurements, ~30 round chondrocytes were randomly examined in each slice preparation to select the Ca^{2+} fluctuation-positive cells generating spontaneous events (>0.025 in Fura-2 ratio) using commercial software (Leica Application Suite X), and recording traces from the positive cells were then analyzed using Fiji/ImageJ software (US. NIH) for examining Ca^{2+} fluctuation amplitude and frequency. Imaging experiments were performed at room temperature (23-25 °C) and PSS was used as the normal bathing solution. For the pretreatments of CNP, ANP and 8-pCPT-cGMP, bone slices were immersed in PSS with the indicated compound for 1 hr at room temperature after Fura-2 loading.

299

300 *Membrane potential monitoring*

Bone slices were perfused with the PSS containing 200 nM oxonol VI at room temperature and analyzed as previously described [33]. To prepare the calibration plot showing the relationship between the fluorescence intensity and membrane potential, saline solutions containing 20 mM, 40 mM, 60 mM or 100 mM KCl were used as bathing solutions. Fluorescence images with excitation at 559 nm and emission at >606 nm were captured at a sampling rate of ~7.0 s using a confocal laser scanning microscope (FV1000; Olympus).

307

308 ***Immunochemical analysis of CaMKII***

309 Bone slices were pretreated with or without CNP were subjected to immunochemical assessments as
 310 previously described [34]. Briefly, for immunohistochemical analysis, bone slices were fixed in 4%
 311 paraformaldehyde and treated with 1% hyaluronidase to enhance immunodetection [35, 36]. After
 312 blocking with fetal bovine serum-containing solution, bone slices were reacted with primary and
 313 Alexa 488-conjugated secondary antibodies and observed with a confocal microscope (FV1000;
 314 Olympus). For immunoblot analysis, bone slices were lysed in the buffer containing 4% sodium
 315 deoxycholate, 20 mM Tris-HCl (pH 8.8) and a phosphatase inhibitor cocktail (100 mM NaF, 10 mM
 316 Na₃PO₄, 1 mM Na₂VO₃ and 20 mM β-glycerophosphate). The resulting lysate proteins were
 317 electrophoresed on SDS-polyacrylamide gels and electroblotted onto nylon membranes for
 318 immunodetection using primary and HRP-conjugated secondary antibodies. Antigen proteins were
 319 visualized using a chemiluminescence reagent and image analyzer (Amersham Imager 600, Cytiva).
 320 The immunoreactivities yielded were quantitatively analyzed by means of Fiji/ImageJ software.

321

322 ***Metatarsal organ culture***

323 Metatarsal bone rudiments were cultured as previously described [24]. Briefly, the three central

324 metatarsal rudiments were dissected from E15.5 mice and cultured in α MEM containing 5 μ g/ml
 325 ascorbic acid, 1 mM β -glycerophosphate pentahydrate, 100 units/ml penicillin, 100 μ g/ml
 326 streptomycin and 0.2% bovine serum albumin (fatty acid free). The explants were analyzed under a
 327 photomicroscope (BZ-X710, Keyence, Japan) for size measurements using Fiji/ImageJ software.

328

329 ***Gene expression analysis***

330 Quantitative RT-PCR analysis was performed as previously described [37]. Total RNA was prepared
 331 from mouse tissues using a commercial reagent (Isogen) and reverse-transcribed using a commercial
 332 kit (ReverTra ACE qPCR-RT kit). The resulting cDNAs were examined by real-time PCR
 333 (LightCycler 480 II, Roche), and the cycle threshold was determined from the amplification curve as
 334 an index for relative mRNA content in each reaction.

335

336 ***Quantification and statistical analysis***

337 All data obtained are presented as the means $\pm$ SEM. with n values indicating the number of
 338 examined mice. Student t -test and ANOVA were used for two-group and multiple group
 339 comparisons, respectively (Prism 7, GraphPad Software Inc.): $p < 0.05$ was considered to be
 340 statistically significant.

341

342 **Acknowledgements:** We thank Jun Matsushita (Graduate School of Pharmaceutical Sciences, Kyoto
343 University) for mouse *in vitro* fertilization. This work was supported in part by the MEXT/JSPS
344 (KAKENHI Grant Number 21H02663 and 20H03802), Platform Project for Supporting Drug
345 Discovery and Life Science Research (JP19am0101092j0003), Takeda Science Foundation,
346 Kobayashi International Scholarship Foundation, the NAKATOMI Foundation, Vehicle Racing
347 Commemorative Foundation and Japan Foundation for Applied Enzymology.

348

349 **Competing interests:** The authors declare no competing financial interests.

350 **Author contributions:** Y.M. and A.I. are equally contributing first authors. Y.M., A.I. and N.O.

351 conducted Ca²⁺ imaging analysis. Y.M., A.I., R.K., T.Y., Y.U., I.Y., S.K. and M.N. conducted

352 biochemical and cell physiological analysis. Y.M. and F.L. conducted membrane potential

353 measurement. Y.U., I.Y., T.H., K.N., Y.M., H.A., and K.N. generated conditional knockout mice.

354 R.K. and T.Y. conducted metatarsal organ culture analysis. Y.M., A.I. and H.T. drafted the

355 manuscript. H.T. oversaw this project.

356

357 **References**

358

- 359 1. Berendsen, A.D., and Olsen, B.R. (2015). Bone development. *Bone*. 80, 14-18.
- 360 2. Nakao, K., Itoh, H., Saito, Y., Mukoyama, M., and Ogawa, Y. (1996). The natriuretic peptide
361 family *Curr Opin Nephrol Hypertens*. 5, 4-11.
- 362 3. Wit, J.M., and Camacho Hübner, C. (2011). Endocrine regulation of longitudinal bone
363 growth. *Endocr Dev*. 21, 30-41.
- 364 4. Peake, N.J., Hobbs, A.J., Pingguan-Murphy, B., Salter, D.M., Berenbaum, F., and
365 Chowdhury, T.T. (2014). Role of C-type natriuretic peptide signalling in maintaining
366 cartilage and bone function. *Osteoarthritis Cartilage*. 22, 1800-1807.
- 367 5. Vasques, G.A., Arnhold, I.J.P., and Jorge, A.A.L. (2014). Role of the natriuretic peptide
368 system in normal growth and growth disorders. *Horm Res Paediatr*. 82, 222-229.
- 369 6. Wit, J.M., Oostdijk, W., Losekoot, M., van Duyvenvoorde, H.A., Ruivenkamp, C.A.L., and
370 Kant, S.G. (2016). MECHANISMS IN ENDOCRINOLOGY: Novel genetic causes of short
371 stature. *Eur J Endocrinol*. 174, R145-R173.
- 372 7. Savarirayan, R., Tofts, L., Irving, M., Wilcox, W., Bacino, C.A., Hoover-Fong, J., Ullot Font,
373 R., Harmatz, P., Rutsch, F., Bober, M.B., et al. (2020). Once-daily, subcutaneous vosoritide
374 therapy in children with achondroplasia: a randomised, double-blind, phase 3,

placebo-controlled, multicentre trial. *Lancet*. 396, 684-692.

8. Krejci, P., Masri, B., Fontaine, V., Mekikian, P.B., Weis, M., Prats, H., and Wilcox, W.R. (2005). Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. *J Cell Sci*. 118, 5089-5100.

9. Kawasaki, Y., Kugimiya, F., Chikuda, H., Kamekura, S., Ikeda, T., Kawamura, N., Saito, T., Shinoda, Y., Higashikawa, A., Yano, F., et al. (2008). Phosphorylation of GSK-3 β by cGMP-dependent protein kinase II promotes hypertrophic differentiation of murine chondrocytes. *J Clin Invest*. 118, 2506-2515.

10. Fleig, A., and Chubanov, V. (2014). Trpm7. *Handb Exp Pharmacol*. 222, 521-546.

11. Qian, N., Ichimura, A., Takei, D., Sakaguchi, R., Kitani, A., Nagaoka, R., Tomizawa, M., Miyazaki, Y., Miyachi, H., Numata, T., et al. (2019). TRPM7 channels mediate spontaneous Ca²⁺ fluctuations in growth plate chondrocytes that promote bone development *Sci Signal*. 12, eaaw4847.

12. Nakao, K., Osawa, K., Yasoda, A., Yamanaka, S., Fujii, T., Kondo, E., Koyama, N., Kanamoto, N., Miura, M., Kuwahara, K., et al. (2015). The local CNP/GC-B system in growth plate is responsible for physiological endochondral bone growth. *Sci Rep*. 5, 10554.

- 392 13. De-Li, D., Peng, Y., Bao-Feng, Y., and Wen-Hui, W. (2008). Hydrogen peroxide stimulates
393 the Ca^{2+} -activated big-conductance K channels (BK) through cGMP signaling pathway in
394 cultured human endothelial cells. *Cell Physiol Biochem.* 22, 119-126.
- 395 14. Fukao, M., Mason, H.S., Britton, F.C., Kenyon, J.L., Horowitz, B., and Keef, K.D. (1999).
396 Cyclic GMP-dependent protein kinase activates cloned BK Ca channels expressed in
397 mammalian cells by direct phosphorylation at serine 1072. *J Biol Chem.* 274, 10927-10935.
- 398 15. White, R.E., Kryman, J.P., El-Mowafy, A.M., Han, G., and Carrier, G.O. (2000).
399 cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate
400 BK(Ca) channel activity in coronary artery smooth muscle cells. *Circ Res.* 86, 897-905.
- 401 16. Guo, J.Y., Zhang, M.H., Jiang, J.Z., Piao, L.H., Fang, X.S., Jin, Z., and Cai, Y.L. (2018). The
402 role of CNP-mediated PKG/PKA-PLC β pathway in diabetes-induced gastric motility disorder.
403 *Peptides.* 110, 47-55.
- 404 17. Huang, J., Zhou, H., Mahavadi, S., Sriwai, W., and Murthy, K.S. (2007). Inhibition of
405 G α_q -dependent PLC- β 1 activity by PKG and PKA is mediated by phosphorylation of RGS4
406 and GRK2. *Am J Physiol Cell Physiol.* 292, C200-C208.
- 407 18. Nalli, A.D., Kumar, D.P., Al-Shboul, O., Mahavadi, S., Kuemmerle, J.F., Grider, J.R., and
408 Murthy, K.S. (2014). Regulation of G $\beta\gamma$ i-dependent PLC- β 3 activity in smooth muscle:

Inhibitory phosphorylation of PLC- β 3 by PKA and PKG and stimulatory phosphorylation of Gai-GTPase-activating protein RGS2 by PKG. *Cell Biochem Biophys.* 70, 867-880.

19. Xia, C., Bao, Z., Yue, C., Sanborn, B.M., and Liu, M. (2001). Phosphorylation and regulation of G-protein-activated phospholipase C- β 3 by cGMP-dependent protein kinases. *J Biol Chem.* 276, 19770-19777.

20. Bibli, S.I., Andreadou, I., Chatzianastasiou, A., Tzimas, C., Sanoudou, D., Kranias, E., Brouckaert, P., Coletta, C., Szabo, C., Kremastinos, D.T., et al. (2015). Cardioprotection by H₂S engages a cGMP-dependent protein kinase G/phospholamban pathway. *Cardiovasc Res.* 106, 432-442.

21. Luc, R., Franz, H., and Rik, C. (1988). Cyclic GMP-dependent protein kinase phosphorylates phospholamban in isolated sarcoplasmic reticulum from cardiac and smooth muscle *Biochem J.* 252, 269-273.

22. Lalli, M.J., Shimizu, S., Sutliff, R.L., Kranias, E.G., and Paul, R.J. (1999). [Ca²⁺]_i homeostasis and cyclic nucleotide relaxation in aorta of phospholamban-deficient mice. *Am J Physiol.* 277, H963-970.

23. Clark, R.B., Hatano, N., Kondo, C., Belke, D.D., Brown, B.S., Kumar, S., Votta, B.J., and Giles, W.R. (2014). Voltage-gated K⁺ currents in mouse articular chondrocytes regulate

426 membrane potential. *Channels*. 4, 179-191.

427 24. Houston, D.A., Staines, K.A., MacRae, V.E., and Farquharson, C. (2016). Culture of murine
 428 embryonic metatarsals: A physiological model of endochondral ossification. *J Vis Exp*.,
 429 e54978.

430 25. Liang, L., Li, X., Moutton, S., Schrier Vergano, S.A., Cogné, B., Saint-Martin, A., Hurst,
 431 A.C.E., Hu, Y., Bodamer, O., Thevenon, J., et al. (2019). De novo loss-of-function KCNMA1
 432 variants are associated with a new multiple malformation syndrome and a broad spectrum of
 433 developmental and neurological phenotypes. *Hum Mol Genet*. 28, 2937-2951.

434 26. Yasoda, A., Komatsu, Y., Chusho, H., Miyazawa, T., Ozasa, A., Miura, M., Kurihara, T.,
 435 Rogi, T., Tanaka, S., Suda, M., et al. (2004). Overexpression of CNP in chondrocytes rescues
 436 achondroplasia through a MAPK-dependent pathway. *Nat Med*. 10, 80-86.

437 27. Martel, G., Hamet, P., and Tremblay, J. (2009). Central role of guanylyl cyclase in natriuretic
 438 peptide signaling in hypertension and metabolic syndrome. *Mol Cell Biochem*. 334, 53-65.

439 28. Zois, N.E., Bartels, E.D., Hunter, I., Kousholt, B.S., Olsen, L.H., and Goetze, J.P. (2014).
 440 Natriuretic peptides in cardiometabolic regulation and disease. *Nat Rev Cardiol*. 11, 403-412.

441 29. Kubacka, M., Kotańska, M., Kazek, G., Waszkielewicz, A.M., Marona, H., Filipek, B., and
 442 Mogilski, S. (2018). Involvement of the NO/sGC/cGMP/K⁺ channels pathway in vascular

relaxation evoked by two non-quinazoline α 1-adrenoceptor antagonists. *Biomed Pharmacother.* *103*, 157-166.

30. Ueda, Y., Yasoda, A., Yamashita, Y., Kanai, Y., Hirota, K., Yamauchi, I., Kondo, E., Sakane, Y., Yamanaka, S., Nakao, K., et al. (2016). C-type natriuretic peptide restores impaired skeletal growth in a murine model of glucocorticoid-induced growth retardation. *Bone.* *92*, 157-167.

31. Yamashita, T., Fujii, T., Yamauchi, I., Ueda, Y., Hirota, K., Kanai, Y., Yasoda, A., and Inagaki, N. (2020). C-Type natriuretic peptide restores growth impairment under enzyme replacement in mice with mucopolysaccharidosis VII *Endocrinology.* *161*, bqaa008.

32. Liu, F., Xu, L., Nishi, M., Ichimura, A., and Takeshima, H. (2021). Enhanced Ca²⁺ handling in thioglycolate-elicited peritoneal macrophages. *Cell Calcium.* *96*, 102381.

33. Yamazaki, D., Tabara, Y., Kita, S., Hanada, H., Komazaki, S., Naitou, D., Mishima, A., Nishi, M., Yamamura, H., Yamamoto, S., et al. (2011). TRIC-A channels in vascular smooth muscle contribute to blood pressure maintenance. *Cell Metab.* *14*, 231-241.

34. Li, Y., Ahrens, M.J., Wu, A., Liu, J., and Dudley, A.T. (2011). Calcium/calmodulin-dependent protein kinase II activity regulates the proliferative potential of growth plate chondrocytes. *Development.* *138*, 359-370.

- 460 35. Ahrens, M.J., and Dudley, A.T. (2011). Chemical pretreatment of growth plate cartilage
461 increases immunofluorescence sensitivity. *J Histochem Cytochem.* 59, 408-418.
- 462 36. Mouser, V.H.M., Melchels, F.P.W., Visser, J., Dhert, W.J.A., Gawlitta, D., and Malda, J.
463 (2016). Yield stress determines bioprintability of hydrogels based on gelatin-methacryloyl
464 and gellan gum for cartilage bioprinting. *Biofabrication.* 8, 035003.
- 465 37. Chengzhu, Z., Ichimura, A., Qian, N., Iida, T., Yamazaki, D., Noma, N., Asagiri, M.,
466 Yamamoto, K., Komazaki, S., Sato, C., et al. (2016). Mice lacking the intracellular cation
467 channel TRIC-B have compromised collagen production and impaired bone mineralization.
468 *Sci Signal.* 9, ra49.
- 469
- 470

Figure legends

Figure 1

Figure 1 CNP-induced facilitation of Ca^{2+} fluctuations in growth plate chondrocytes.

(A) Fura-2 imaging of round chondrocytes pretreated with or without natriuretic peptides. Femoral bone slices prepared from wild-type C57BL embryos were pretreated with or without CNP and ANP, and subjected to Ca^{2+} imaging. Representative recording traces from three cells are shown in each pretreatment group (upper panels). The effects of CNP and ANP pretreatments on spontaneous Ca^{2+} fluctuations are summarized (lower panels). The fluctuation-positive cell ratio, fluctuation amplitude and frequency were statistically analyzed, and significant differences from the control vehicle pretreatment are marked with asterisks (* $p < 0.05$ and ** $p < 0.01$ in one-way ANOVA and Dunnett's test). The data are presented as the means $\pm$ SEM, with n values indicating the number of examined mice. (B) Fura-2 imaging of round chondrocytes prepared from chondrocyte-specific *Npr2*-knockout (*Npr2^{fl/fl}, Col2a1-Cre^{+/+}*) and control (*Npr2^{fl/fl}, Col2a1-Cre^{-/-}*) mice. The bone slices were pretreated with CNP, and then subjected to Ca^{2+} imaging. Representative recording traces are shown (left panels) and the CNP-pretreated effects are summarized (right graphs); significant differences from the wild-type group are marked with asterisks (* $p < 0.05$ in one-way ANOVA and Tukey's test). The data are presented as the means $\pm$ SEM, with n values indicating the number of examined mice.

Figure 2

Figure 2 Contribution of PKG to CNP-facilitated Ca^{2+} fluctuations.

(A) Facilitated Ca^{2+} fluctuations in round chondrocytes pretreated with the PKG activator 8-pCPT-cGMP. Wild-type bone slices were pretreated with or without the cGMP analog, and then subjected to Ca^{2+} imaging. Representative recording traces are shown (left panels), and the pharmacological effects are summarized (right graphs). Significant differences between control and 8-pCPT-cGMP pretreatments are marked with asterisks (** $p < 0.01$ in t -test). The data are presented as the means $\pm$ SEM, with n values indicating the number of examined mice. **(B)** Attenuation of CNP-facilitated Ca^{2+} fluctuations by the PKG inhibitor KT5823. Wild-type bone slices were pretreated with CNP, and then subjected to Ca^{2+} imaging. Representative recording traces are shown (left panel), and KT5823-induced effects are summarized (right graphs). Significant KT5823-induced shifts are marked with asterisks (** $p < 0.01$ in t -test). The data are presented as the means $\pm$ SEM, with n values indicating the number of examined mice.

Figure 3

Figure 3 Contribution of BK channels to CNP-facilitated Ca^{2+} fluctuations.

(A) Attenuation of CNP-facilitated Ca^{2+} fluctuations by the BK channel inhibitor paxilline in round chondrocytes. Wild-type bone slices were pretreated with or without CNP, and then subjected to Ca^{2+} imaging. Representative recording traces are shown (left panels), and paxilline-induced effects are summarized (right graphs). Significant paxilline-induced shifts are marked with asterisks (* $p < 0.05$ and ** $p < 0.01$ in one-way ANOVA and Tukey's test). The data are presented as the means $\pm$ SEM, with n values indicating the number of examined mice. (B) Ca^{2+} fluctuations facilitated by the BK channel activator NS1619 in *Npr2*-deficient chondrocytes. Bone slices were prepared from the chondrocyte-specific *Npr2*-knockout and control embryos, and NS1619-induced effects were examined in Ca^{2+} imaging. Representative recording traces are shown (left panels), and the effects of NS1619 are summarized (right graphs). Significant NS1619-induced shifts are marked with asterisks (** $p < 0.01$ in one-way ANOVA and Tukey's test). The data are presented as the means $\pm$ SEM, with n values indicating the number of examined mice.

Figure 4

Figure 4 BK channel-mediated hyperpolarization induced by CNP.

(A) Oxonol VI imaging of round chondrocytes pretreated with or without CNP. Wild-type bone slices were pretreated with or without CNP, and then subjected to membrane potential imaging. During contiguous treatments with high-K⁺ solutions, cellular fluorescence intensities were monitored and normalized to the maximum value in the 100 mM KCl-containing solution to yield the fractional intensity (left panel). The resting fractional intensities were quantified and statistically analyzed in CNP- and vehicle-pretreated cells (middle graph). For preparing the calibration plot (right panel), the data from ten cells in bathing solutions containing 4 (normal solution), 20, 40, 60 and 100 mM KCl are summarized; red and black lines indicate the estimated resting membrane potentials of CNP- and vehicle-pretreated cells, respectively. (B) Effects of the BK channel inhibitor paxilline on resting membrane potential in round chondrocytes. Recording data from ten cells pretreated with or without CNP were averaged (left panel), and the fractional intensities elevated by paxilline are summarized (right graph). (C) Effects of the BK channel activator NS1619 on membrane potential in round chondrocytes. Recording data from ten cells pretreated with or without CNP were averaged (left panel), and the fractional intensities in normal, 20 mM KCl and NS1619-containing 20 mM KCl solutions are summarized (right graph). Significant differences between CNP- and vehicle-pretreated cells are indicated by asterisks in A (***p*<0.01 in *t*-test) and in C (***p*<0.01 in one-way ANOVA and Dunn's test). The data are presented as the means $\pm$ SEM. with *n* values indicating the number of examined mice.

Figure 5

Figure 5 Enhanced TRPM7-mediated Ca²⁺ entry by CNP treatments.

(A) Inhibition of CNP-facilitated Ca²⁺ fluctuations by the TRPM7 inhibitor FTY720 in round chondrocytes. Wild-type bone slices were pretreated with CNP, and then subjected to Ca²⁺ imaging. Representative recording traces are shown (left panel), and the effects of FTY720 are summarized (right graphs). Significant FTY720-induced shifts are marked with asterisks (***p* < 0.01 in *t*-test). The data are presented as the means $\pm$ SEM, with *n* values indicating the number of examined mice. **(B)** Ca²⁺ fluctuations facilitated by the TRPM7 channel activator NNC550396 in *Npr2*-deficient round chondrocytes. Bone slices were prepared from the chondrocyte-specific *Npr2*-knockout and control embryos, and NNC550396-induced effects were examined in Ca²⁺ imaging. Representative recording traces are shown (left panels) and the effects of NNC550396 on Ca²⁺ fluctuations are summarized (right graphs). Significant NNC550396-induced shifts in each genotype are marked with asterisks (***p* < 0.01 in one-way ANOVA and Tukey's test). The data are presented as the means $\pm$ SEM, with *n* values indicating the number of examined mice.

Figure 6

Figure 6 CaMKII activation in CNP-treated round chondrocytes.

(A) Immunohistochemical staining against phospho-CaMKII (p-CaMKII) in round chondrocytes. Wild-type bone slices were pretreated with or without CNP and the CaMKII inhibitor KN93, and then subjected to immunostaining with antibody to p-CaMKII. DAPI (4', 6-diamidino-2- phenylindole) was used for nuclear staining. Lower panels show high-magnification views of white-dotted regions in upper panels (scale bars, 10 μm). (B) Immunoblot analysis of total CaMKII and p-CaMKII in growth plate cartilage. Growth plate lysates were prepared from wild-type bone slices pretreated with or without CNP, and subjected to immunoblot analysis with antibodies against total CaMKII and p-CaMKII (upper panel). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also analyzed as a loading control. The immunoreactivities observed were densitometrically quantified and are summarized (lower graph). A significant difference between CNP- and vehicle-pretreatments is marked with an asterisk (* $p < 0.05$ in one-way ANOVA and Tukey's test). The data are presented as the means $\pm$ SEM, with n values indicating the number of examined mice.

Figure 7

Figure 7 Contribution of TRPM7 and BK channels to CNP-facilitated bone outgrowth.

(A) Loss of CNP-facilitated outgrowth in *Trpm7*-deficient bones. Metatarsal rudiments isolated from the chondrocyte-specific *Trpm7*-knockout (*Trpm7^{fl/fl}, 11Enh-Cre^{+/-}*) and control (*Trpm7^{fl/fl}, 11Enh-Cre^{-/-}*) embryos were precultured in normal medium for 6 days, and then cultured in medium supplemented with or without CNP for 3 days. Representative images of cultured metatarsals are shown (left panels; scale bar, 0.3 mm), and longitudinal bone outgrowth during the CNP-supplemented period was statistically analyzed in each genotype group (right graphs). Significant CNP-supplemented effects are marked with asterisks (* $p < 0.05$ in *t*-test). The data are presented as the means $\pm$ SEM, with *n* values indicating the number of examined mice. **(B)** Stimulated bone outgrowth by the BK channel activator NS1619. Metatarsal rudiments isolated from wild-type and the chondrocyte-specific *Trpm7*-knockout embryos were precultured in normal medium for 5 days, and then cultured in medium supplemented with or without NS1619 for 4 days. Representative images of cultured metatarsals are shown (left panels; scale bar, 0.3 mm), and longitudinal bone outgrowth during the NS1619-supplemented period was statistically analyzed in each genotype group (right graphs). A significant NS1619-supplemented effect is marked with asterisks (* $p < 0.05$ in *t*-test). The data are presented as the means $\pm$ SEM, with *n* values indicating the number of examined mice.

Figure legends for figure supplements

Figure 1-figure supplement 1 Chondrocyte-specific *Npr2* ablation.

(A) Organization of floxed and deleted *Npr2* alleles. The chondrocyte-specific *Npr2*-knockout (*Npr2*^{fl/fl}, *Col2a1-Cre*^{+/-}) mice were previously generated [12]. In this study, genotyping primers were newly designed, and *Npr2* ablation was evaluated in growth plates. The genomic map shows PCR primers for detecting the mutated *Npr2* alleles and *Npr2* mRNA. (B) *Npr2* gene ablation in various tissues from the chondrocyte-specific *Npr2*-knockout mice. Genomic DNAs were prepared from tissues (Gp, humeral growth plate; Br, brain; Lu, lung; Hr, heart; Lv, liver; Ki, kidney) from the E17.5 chondrocyte-specific *Npr2*-knockout and control embryos, and subjected to PCR analysis to detect the floxed and deleted *Npr2* alleles; the *Col2a1-Cre* transgene was also examined. (C) Reduction of *Npr2* mRNA in mutant growth plates prepared from the chondrocyte-specific *Npr2*-knockout mice. Total RNAs were prepared from humeral growth plates from the E17.5 embryos, and subjected to RT-PCR analysis for estimating *Npr2* mRNA content. 18S ribosomal RNA was examined as an internal control. The relative mRNA contents were estimated from cycle thresholds in RT-PCR reactions and are summarized in the bar-graph. The data represent means ± SEM, and the numbers of mice examined are shown in parentheses. A significant difference between the genotype is marked with an asterisk (***p* < 0.01 in *t*-test).

589

590 **Figure 1-figure supplement 2 Gene expression analysis in wild-type growth plate chondrocytes.**

591 Total RNAs were prepared from growth plate sections packed with round chondrocytes or enriched with
592 columnar and hypertrophic chondrocytes, and subjected to RT-PCR analysis. The cycle threshold (Ct) was
593 determined for each RT-PCR reaction for estimating relative mRNA content. The data represent the mean ±
594 SEM, and the numbers of mice examined are shown in parentheses. Significant differences between the
595 growth plate sections are marked with asterisks (*p < 0.05 and **p < 0.01 in t-test). n.d.: not detectable.

596

597 **Figure 3-figure supplement 3 Effects of PLC inhibitor U73122 on CNP-facilitated Ca^{2+} fluctuations.**

598 In Ca^{2+} imaging, U73122 was bath-applied to wild-type round chondrocytes pretreated with or without CNP.

599 Representative recording traces are shown (left panels), and the effects of U73122 are summarized (right

600 bar-graphs). Data represent means $\pm$ SEM, and the numbers of cells and mice examined are shown in

601 parentheses in the keys and graph bars, respectively. Significant differences between before and after the

602 U73122 treatment are marked with asterisks (* $p < 0.05$ and ** $p < 0.01$ in one-way ANOVA and Tukey's test).

Figure 3-figure supplement 4 Store Ca²⁺ release in CNP-treated round chondrocytes.

(A) Store Ca²⁺ release triggered by 1-oleoyl lysophosphatidic acid (LPA) in wild-type round chondrocytes pretreated with or without CNP. Representative recording traces are shown (left panels), and LPA-evoked Ca²⁺ responses are summarized (right graphs). Data represent means ± SEM, and the numbers of cells and mice examined are shown in parentheses in the keys and graph bars, respectively. No significant differences were observed between CNP- and vehicle-pretreated groups (one-way ANOVA and Tukey's test). **(B)** Ca²⁺ leak responses evoked by the SERCA pump inhibitor thapsigargin (TG) in wild-type round chondrocytes pretreated with or without CNP. Representative recording traces are shown (left panels), and TG-evoked Ca²⁺ responses are summarized (right bar-graphs). Data represent means ± SEM, and the numbers of cells and mice examined are shown in parentheses in the keys and graph bars, respectively. No significant differences were observed between CNP- and vehicle-pretreated groups (*t*-test).

614 **Figure 7-figure supplement 5 Proposed CNP-evoked signaling in growth plate chondrocytes.**

615 **(A)** The schematic diagram representing the NPR2-PKG-BK channel-TRPM7 channel-CaMKII axis proposed
616 as an essential CNP signaling cascade in growth plate chondrocytes. Previous studies proposed that the
617 RAF-MEK-ERK axis is also involved in growth plate CNP signaling [8]. **(B)** The schematic diagram
618 representing the NO- and ANP/BNP-induced relaxation signaling in vascular smooth muscle.

619

620 Key Resources Table

Reagent or Resource	Source	Identifiers
Antibodies		
Anti-phospho-CaMKII (Thr 286)	Cell Signaling Technology	Cat#12716; RRID: AB_2713889
Anti-CaMKII	Abcam	Cat#EP1829Y; RRID: AB_868641
Anti-GAPDH	Sigma-Aldrich	Cat#G9545; RRID: AB_796208
Anti-rabbit IgG-HRP	Santa Cruz	Cat#sc-2357; RRID: AB_628497
Anti-rabbit Alexa Flour 488	Invitrogen	Cat#A-11008; RRID: AB_143165
Chemicals, peptides, and recombinant proteins		
ANP (Human, 1-28)	Peptide Institute	Cat#4135
CNP-22 (Human)	Peptide Institute	Cat#4229

FTY720	Sigma-Aldrich	SML0700; CAS: 162359-56-0
Fura-2AM	DOJINDO	F025; CAS: 108964-32-5
Hyaluronidase from sheep testes	Sigma-Aldrich	H2126; CAS: 37326-33-3
KN93	WAKO	115-00641; CAS: 139298-40-1
KT5823	Cayman Chemical	10010965; CAS: 126643-37-6
NNC 550396 dihydrochloride	Tocris Bioscience	2268; CAS: 357400-13-6
NS1619	Sigma-Aldrich	N170; CAS: 153587-01-0
1-oleoyl lysophosphatidic acid	Cayman Chemical	62215; CAS: 325465-93-8

Oxonol VI	Sigma-Aldrich	75926; CAS: 64724-75-0
Paxilline	Tocris Bioscience	2006; CAS: 57186-25-1
8-pCPT-cGMP	Biolog	C009; CAS: 51239-26-0
Thapsigargin	Nacalai Tesque	33637-31; CAS: 67526-95-8
U73122	Sigma-Aldrich	U6756; CAS: 112648-68-7
Critical commercial assays		
Amersham ECL Prime Western Blotting Detection Reagent	Cytiva	Cat#RPN2232
ISOGEN	NipponGene	Cat#319-90211
ReverTra Ace® qPCR RT Master Mix with gDNA Remover	TOYOBO	Cat#FSQ-301

Experimental models: Organisms/strains		
Mouse: C57BL/6J	The Jackson Laboratory	Jax: 000664
<i>Trpm7^{fl/fl}</i> , <i>11Enh-Cre</i> mice	[11]	N/A
<i>Npr2^{fl/fl}</i> , <i>Col2a1-Cre</i> mice	[12]	N/A
Oligonucleotides		
Mouse <i>Npr1</i> For: AACAAAGGAGAACAGCAGCAAC	This paper	N/A
Mouse <i>Npr1</i> Rev: TATCAAATGCCTCAGCCTGGA	This paper	N/A
Mouse <i>Npr2</i> For: GGCCCCATCCCTGATGAAC	This paper	N/A
Mouse <i>Npr2</i> Rev: CCTGGTACCCCTTCCTGTA	This paper	N/A
Mouse <i>Npr3</i> For: GGTATGGGGACTTCTCTGTG	This paper	N/A
Mouse <i>Npr3</i> Rev: TCTGGTCTCATCTAGTCTCA	This paper	N/A
FIFor: GTAACCTGGGTAGACTAGTTGTTGG	This paper	N/A
DeIFor: TGTTATTTTGTGAGATGACG	This paper	N/A
Rev: ATGGTGGAGGAGGTCTTTAATTCC	This paper	N/A
Col2a1-Cre For: CGTTGTGAGTTGGATAGTTG	This paper	N/A

Col2a1-Cre Rev: CATTGCTGTCACTTGGTCGT	This paper	N/A
Mouse <i>Prkg1</i> For: ATGGACTTTTTGTGGGACTC	This paper	N/A
Mouse <i>Prkg1</i> Rev: GGTTTTTCATTGGATCTGGGC	This paper	N/A
Mouse <i>Prkg2</i> For: TTGCGGAAGAAAATGATGTCTG	This paper	N/A
Mouse <i>Prkg2</i> Rev: GAATGGGGAGGTTGAGGAGAA	This paper	N/A
Mouse <i>Kcnma</i> For: AATGCACTTCGAGGAGGCTA	[32]	N/A
Mouse <i>Kcnma</i> Rev: CTCAGCCGGTAAATTCCAAA	[32]	N/A
Mouse <i>Kcnmb1</i> For: ACAACTGTGCTGCCCCCTCTA	This paper	N/A
Mouse <i>Kcnmb1</i> Rev: CACTGTTGGTTTTGATCCCG	This paper	N/A
Mouse <i>Kcnmb2</i> For: TCAGGAGACACCAACACTTC	This paper	N/A
Mouse <i>Kcnmb2</i> Rev: AGTTAGTTTCACCATAGCAA	This paper	N/A
Mouse <i>Kcnmb3</i> For: GTGGATGACGGGCTGGACTT	This paper	N/A
Mouse <i>Kcnmb3</i> Rev: GCACTTGGGGTTGGTCCTGA	This paper	N/A
Mouse <i>Kcnmb4</i> For: CTCCTGACCAACCCCAAGT	This paper	N/A
Mouse <i>Kcnmb4</i> Rev: TAAAATAGCAAGTGAATGGC	This paper	N/A
Mouse <i>Kcnn1</i> For: TCAAAAATGCTGCTGCAAAC	[32]	N/A

Mouse <i>Kcnn1</i> Rev: TCGTTCACCTTCCCTTGTTTC	[32]	N/A
Mouse <i>Kcnn2</i> For: GATCTGGCAAAGACCCAGAA	[32]	N/A
Mouse <i>Kcnn2</i> Rev: GAAGTCCCTTTGCTGCTGTC	[32]	N/A
Mouse <i>Kcnn3</i> For: ACTTCAACACCCGATTCGTC	[32]	N/A
Mouse <i>Kcnn3</i> Rev: GGAAAGGAACGTGATGGAGA	[32]	N/A
Mouse <i>Kcnn4</i> For: GGCACCTCACAGACACACTG	[32]	N/A
Mouse <i>Kcnn4</i> Rev: TTTCTCCGCCTTGTTGAACT	[32]	N/A
Mouse <i>Plcb1</i> For: CCCAAGTTGCGTGAACCTTCT	[33]	N/A
Mouse <i>Plcb1</i> Rev: GTTGCCAAGCTGAAAACCTC	[33]	N/A
Mouse <i>Plcb2</i> For: ACATCCAGGAAGTGGTCCAG	[33]	N/A
Mouse <i>Plcb2</i> Rev: CGCACCGACTCCTTTACTTC	[33]	N/A
Mouse <i>Plcb3</i> For: CAGGCCAGCACAGAGACATA	[33]	N/A
Mouse <i>Plcb3</i> Rev: AGGATGCTGGCAATCAAATC	[33]	N/A
Mouse <i>Plcg1</i> For: AACGCTTTGAGGACTGGAGA	This paper	N/A
Mouse <i>Plcg1</i> Rev: CTCCTCAATCTCTCGCAAGG	This paper	N/A
Mouse <i>Plcg2</i> For: AACCCCAACCCACACGAGTC	This paper	N/A

Mouse <i>Plcg2</i> Rev: AATGTTTCACCTTGCCCCTG	This paper	N/A
Mouse <i>Trpm7</i> For: ATTGCTTAGTTTTGGTGTTT	[11]	N/A
Mouse <i>Trpm7</i> Rev: GATTGTCTGGGAGAGTGGAGT	[11]	N/A
Mouse <i>Camk2a</i> For: CACCACCATTGAGGACGAAG	This paper	N/A
Mouse <i>Camk2a</i> Rev: GGTTCAAAGGCTGTCATTCC	This paper	N/A
Mouse <i>Camk2b</i> For: AAGCAGATGGAGTCAAGCC	This paper	N/A
Mouse <i>Camk2b</i> Rev: TGCTGTCTGGAAGATTCCAGG	This paper	N/A
Mouse <i>Camk2d</i> For: GATAAACAACAAAGCCAACG	This paper	N/A
Mouse <i>Camk2d</i> Rev: GTAAGCCTCAAAGTCCCCAT	This paper	N/A
Mouse <i>Camk2g</i> For: CAAGAACAGCAAGCCTATCC	This paper	N/A
Mouse <i>Camk2g</i> Rev: CCTCTGACTGACTGGTGCGA	This paper	N/A
Mouse <i>Pde2a</i> For: ATCTTTGACCACTTCTCTCG	This paper	N/A
Mouse <i>Pde2a</i> Rev: CATAACCCACTTCAGCCATC	This paper	N/A
Mouse <i>Pde3a</i> For: AACTATACCTGCTCGGACTC	This paper	N/A
Mouse <i>Pde3a</i> Rev: TTCGTGCGGCTTTATGCTGG	This paper	N/A
Mouse <i>Pde3b</i> For: ATTCCAAAGCAGAGGTCATC	This paper	N/A

Mouse <i>Pde3b</i> Rev: GTTAGAGAGCCAGCAGACAC	This paper	N/A
Mouse <i>Pde5a</i> For: GACCCTTGCGTTGCTCATTG	This paper	N/A
Mouse <i>Pde5a</i> Rev: TGATGGAGTGACAGTACAGC	This paper	N/A
Mouse <i>Pde6a</i> For: AACCCACCCGCTGACCACTG	This paper	N/A
Mouse <i>Pde6a</i> Rev: CTCTTCCTTCTTGTTGACGA	This paper	N/A
Mouse <i>Pde6b</i> For: TCCGGGCCTATCTAACTGC	This paper	N/A
Mouse <i>Pde6b</i> Rev: AGAAGACAATTTCCCGGCCAT	This paper	N/A
Mouse <i>Pde6c</i> For: TTGCTCAGGAAATGGTTATG	This paper	N/A
Mouse <i>Pde6c</i> Rev: GAAACAGAACTCGTACAGGT	This paper	N/A
Mouse <i>Pde6d</i> For: CCCAAGAAAATCCTCAAGTG	This paper	N/A
Mouse <i>Pde6d</i> Rev: ACAAAGCCAAACTCGAAGAA	This paper	N/A
Mouse <i>Pde6g</i> For: AAGGGTGAGATTCGGTCAGC	This paper	N/A
Mouse <i>Pde6g</i> Rev: TCATCCCCAAACCCTTGAC	This paper	N/A
Mouse <i>Pde6h</i> For: GGCAGACTCGACAGTTCAAGA	This paper	N/A
Mouse <i>Pde6h</i> Rev: CTCCAGATGGCTGAACGCT	This paper	N/A
Mouse <i>Pde10a</i> For: CATCCGCAAAGCCATCATCG	This paper	N/A

Mouse <i>Pde10a</i> Rev: TCTCATCACCCCTCAGCCCAG	This paper	N/A
Mouse <i>Lpar1</i> For: GCTTGGTGCCTTTATTGTCT	This paper	N/A
Mouse <i>Lpar1</i> Rev: GGTAGGAGTAGATGATGGGG	This paper	N/A
Mouse <i>Lpar2</i> For: AGTGTGCTGGTATTGCTGAC	This paper	N/A
Mouse <i>Lpar2</i> Rev: TTTGATGGAGAGCCTGGCAG	This paper	N/A
Mouse <i>Lpar3</i> For: ACTTTCCCTTCTACTACCTG	This paper	N/A
Mouse <i>Lpar3</i> Rev: GTCTTTCCACAGCAATAACC	This paper	N/A
Mouse <i>Lpar4</i> For: CCTCAGTGGTGGTATTTTCAG	This paper	N/A
Mouse <i>Lpar4</i> Rev: CACAGAAGAACAAGAAACAT	This paper	N/A
Mouse <i>Lpar5</i> For: AACACGACTTCTACCAACAG	This paper	N/A
Mouse <i>Lpar5</i> Rev: AAGACCCAGAGAGCCAGAGC	This paper	N/A
Mouse <i>Lpar6</i> For: TACTTTGCCATTTTCGGATTT	This paper	N/A
Mouse <i>Lpar6</i> Rev: GCACTTCCTCCCATCACTGT	This paper	N/A
Mouse <i>Atp2a1</i> For: CAAAACAGGGACCCTCACCA	[32]	N/A
Mouse <i>Atp2a1</i> Rev: GCCAGTGATGGAGAACTCGT	[32]	N/A
Mouse <i>Atp2a2</i> For: AAACCAGATGTCCGTGTGCA	[32]	N/A

Mouse <i>Atp2a2</i> Rev: TGATGGCACTTCACTGGCTT	[32]	N/A
Mouse <i>Atp2a3</i> For: CCTCGGTCATCTGCTCTGAC	[32]	N/A
Mouse <i>Atp2a3</i> Rev: CGTGGTACCCGAAATGGTGA	[32]	N/A
Mouse <i>Pln</i> For: TACCTCACTCGCTCGGCTAT	This paper	N/A
Mouse <i>Pln</i> Rev: TGACGGAGTGCTCGGCTTTA	This paper	N/A
Mouse <i>Pthlh</i> For: CTCCCAACACCAAAAACCAC	[11]	N/A
Mouse <i>Pthlh</i> Rev: GCTTGCCTTTCTTCTTCTTC	[11]	N/A
Mouse <i>Col10a1</i> For: CAAGCCAGGCTATGGAAGTC	[11]	N/A
Mouse <i>Col10a1</i> Rev: AGCTGGGCCAATATCTCCTT	[11]	N/A
Mouse <i>Col2a1</i> For: CACACTGGTAAGTGGGGCAAGACCG	[11]	N/A
Mouse <i>Col2a1</i> Rev: GGATTGTGTTGTTTCAGGGTTCGGG	[11]	N/A
Mouse <i>18S</i> For: AGACAAATCGCTCCACCAAC	[11]	N/A
Mouse <i>18S</i> Rev: CTCAACACGGGAAACCTCAC	[11]	N/A
Mouse <i>Actb</i> For: CATCCGTAAAGACCTCTATGCCAAC	[11]	N/A

Mouse <i>Actb</i> Rev: ATGGAGCCACCGATCCACA	[11]	N/A
Mouse <i>Gapdh</i> For: TGTGTCCGTCGTGGATCTGA	[11]	N/A
Mouse <i>Gapdh</i> Rev: TTGCTGTTGAAGTCGCAGGAG	[11]	N/A
Software and algorithms		
Adobe Illustrator	Adobe Systems	http://www.adobe.com/products/illustrator.html
GraphPad Prism v7	GraphPad	https://www.graphpad.com/
ImageJ	N/A	https://imagej.nih.gov/ij/
Leica Application Suite X	Leica Microsystems	https://www.leica-microsystems.com/products/microscope-software/p/leica-las-x-ls/

Figure 6B-Source Data

622 **Figure 6B-Source Data 1**

623 Data related to Figure 6B – Uncropped images.

Figure 1-figure supplement 1B-Source Data 1

624 **Figure 1-figure supplement 1B-Source Data 1**

625 Data related to Figure 1-figure supplement 1B – Uncropped images.

626

Figure 1-figure supplement 1B-Source Data 2

627 **Figure 1-figure supplement 1B-Source Data 2**

628 Data related to Figure 1-figure supplement 1B – Uncropped images.